Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065288 | 1.00 | MAPT (0.43) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3068618 | 0.88 | ALDH1A1 (0.41) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3068622 | 0.88 | ALDH1A1 (0.41) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3220534 | 0.81 | ADORA3 (0.45) | MAPTALDH1A1GRIK1GRIK2NR1I2 | |
| SCHEMBL3220525 | 0.81 | ADORA3 (0.45) | MAPTALDH1A1GRIK1GRIK2NR1I2 | |
| SCHEMBL3066159 | 0.80 | ALDH1A1 (0.42) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3066157 | 0.80 | ALDH1A1 (0.42) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3224579 | 0.79 | ALDH1A1 (0.46) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL3059059 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1CNR1CNR2FAAH | |
| SCHEMBL13491253 | 0.78 | ADORA3 (0.49) | MAPTALDH1A1HPGDGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267828-A1 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267828-A1 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | LIPA, LPL, PNLIP | MAPT 4554/4885ALDH1A1 1114/4885CNR1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.